肾移植后避免或停用类固醇会增加急性排斥反应的风险,但会降低心血管风险。一项荟萃分析。
Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis.
机构信息
Centre for Evidence in Transplantation, Clinical Effectiveness Unit, Royal College of Surgeons of England, United Kingdom.
出版信息
Transplantation. 2010 Jan 15;89(1):1-14. doi: 10.1097/TP.0b013e3181c518cc.
INTRODUCTION
The morbidity related to long-term steroid therapy has led to continued interest in withdrawal of steroids from immunosuppressant regimens after renal transplantation. A number of recent trials have provided long-term information regarding the risks and benefits of steroid avoidance or withdrawal (SAW).
METHODS
A literature search was performed using Ovid Medline, Embase, the Cochrane Library, and the Transplant Library. Randomized controlled trials comparing a maintenance steroid group with complete avoidance or withdrawal of steroids were selected. All studies were assessed for methodological quality. Trials were pooled by meta-analysis to provide summary effects (relative risk [RR] or weighted mean difference) with 95% confidence intervals (CI).
RESULTS
Thirty-four studies including 5,637 patients met the inclusion criteria. SAW regimens significantly increased the risk of acute rejection (AR) over maintenance steroids (RR 1.56, CI 1.31-1.87, P<0.0001). No significant differences in corticosteroid resistant AR, patient survival, or graft survival were observed. Serum creatinine was increased and creatinine clearance was reduced with SAW. Cardiovascular risk factors including incidence of hypertension (RR 0.90, CI 0.85-0.94, P<0.0001), new onset diabetes (RR 0.64, CI 0.50-0.83, P=0.0006), and hypercholesterolemia (RR 0.76, CI 0.67-0.87, P<0.0001) were reduced significantly by SAW.
CONCLUSION
Despite an increase in the risk of AR with SAW protocols, there is only a small effect on graft function with no measurable effect on graft or patient survival. There are significant benefits in cardiovascular risk profiles after SAW. SAW protocols would seem justified with current immunosuppressive protocols in low-risk recipients.
简介
长期类固醇治疗的发病率导致人们持续关注肾移植后从免疫抑制方案中撤停类固醇。一些最近的试验提供了关于避免或撤停类固醇(SAW)的风险和获益的长期信息。
方法
使用 Ovid Medline、Embase、Cochrane 图书馆和 Transplant 图书馆进行文献检索。选择了比较维持类固醇组与完全避免或撤停类固醇的随机对照试验。所有研究均进行了方法学质量评估。通过荟萃分析对试验进行汇总,以提供具有 95%置信区间(CI)的汇总效应(相对风险 [RR]或加权均数差)。
结果
34 项研究共纳入 5637 例患者,符合纳入标准。SAW 方案显著增加了急性排斥反应(AR)的风险(RR 1.56,CI 1.31-1.87,P<0.0001)。未观察到皮质激素抵抗性 AR、患者生存率或移植物生存率的显著差异。SAW 后血清肌酐升高,肌酐清除率降低。SAW 显著降低了心血管危险因素的发生率,包括高血压(RR 0.90,CI 0.85-0.94,P<0.0001)、新发糖尿病(RR 0.64,CI 0.50-0.83,P=0.0006)和高胆固醇血症(RR 0.76,CI 0.67-0.87,P<0.0001)。
结论
尽管 SAW 方案增加了 AR 的风险,但对移植物功能的影响很小,对移植物或患者生存率没有可测量的影响。SAW 后心血管风险谱有显著获益。在低危受者中,SAW 方案似乎与当前的免疫抑制方案是合理的。